Healthcare ❯Pharmaceuticals ❯Weight Loss Drugs ❯Ozempic

Wegovy

Novo Nordisk Cuts 2025 Outlook and Names New CEO as Shares Plunge

The leadership change follows intensified pressure from compounded copycats, with rival Eli Lilly therapies adding to slowed sales momentum.

Novo Nordisk CEO Steps Down Following Share Price Collapse

Senate Grills Novo Nordisk CEO Over High U.S. Prices for Ozempic and Wegovy

Weight-Loss Drug Market Heats Up as Prices Drop and New Treatments Emerge